Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Weigh Up Benefits Of Big Bayer Restructuring

Executive Summary

The investment community has praised Bayer's bosses for a "much-needed shake-up and slimming down of the organisation" as management increases its focus on the core pharmaceuticals business and looks to exit animal health.

You may also be interested in...



Coppertone, Dr. Scholl’s On The Block As Bayer Narrows Consumer Health Focus

Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.

Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval

EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC124261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel